No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
COMPARATIVE STUDY OF EFFICACY OF DEXMEDETOMIDINE- BUPIVACAINE AND BUPRENORPHINE-BUPIVACAINE IN SPINAL ANAESTHESIA IN LOWER ABDOMINAL AND LOWER LIMB SURGERIES
Abstract
BACKGROUND The addition of local anaesthetics with adjuvants improves the efcacy of subarachnoid block. The most commonly used drugs are opioids and newer drugs like dexmedetomidine said to be safer and effective spinal adjuvant. To compare and evaluate sensory , motor blockade and haemodynamic effects between dexmedetomidine -AIMS & OBJECTIVES bupivacaine and buprenorphine - bupivacaine groups. A prospective randomised study was conducted on 60 patients posted forMETHODS elective lower abdominal and lower limb surgeries belonging to ASA 1 & 2 grade. Patients were randomly divided into 2 groups, each group containing 30 patients. Group D receives 3ml (15mg) of 0.5% hyperbaric bupivacaine with 5 mcg dexmedetomidine in 0.5 ml NS while group B receives 3ml (15mg) of 0.5% hyperbaric bupivacaine with buprenorphine 75 mcg in 0.5 ml NS. Sensory , motor blockade and haemodynamic effects were recorded between two groups. There was no signicant difference between two groups regarding demographic data andRESULTS duration of surgery. The rapid onset of sensory block and prolonged duration of sensory and motor blockade achieved with 5μg of dexmedetomidine combined with bupivacaine for spinal anaesthesia suggests that the drug is useful in surgeries requiring prompt onset.
ResearchGate has not been able to resolve any citations for this publication.
Comparison of efficacy of buprenorphine adjuvant to bupivacaine and plain bupivacaine in spinal anaesthesia for lower abdominal and lower limb surgeries
Background and Aims
Transurethral resection of the prostate is a commonly performed urological procedure in elderly men with spinal anaesthesia being the technique of choice. Use of low-dose spinal anesthetic drug with adjuvants is desirable. This study compares the sensorimotor effects of addition of buprenorphine or dexmedetomidine to low-dose bupivacaine.
Methods
Sixty patients were randomly allocated to three different groups. All received 1.8 mL 0.5% hyperbaric bupivacaine intrathecally. Sterile water (0.2 mL) or buprenorphine (60 μg) or dexmedetomidine (5 μg) was added to control group (Group C), buprenorphine group (Group B), and dexmedetomidine group (Group D), respectively. Time to the first analgesic request was the primary objective, and other objectives included the level of sensory-motor block, time to two-segment regression, time to S1 sensory regression and time to complete motor recovery. ANOVA and post hoc test were used for statistical analysis. The value of P < 0.05 was considered statistically significant.
Results
All sixty patients completed the study. Postoperative analgesia was not required in the first 24 h in a total of 10 (50%), 12 (60%) and 15 (75%) patients in groups C, B, and D, respectively. Time to S1 regression was 130 ± 46 min (Group C), 144 ± 51.3 min (Group B) and 164 ± 55.99 min (Group D), P = 0.117. Time to complete motor recovery was 177 ± 56.9 min (Group C), 236 ± 60 min (Group B) and 234 ± 61.71 min (Group D), P < 0.001.
Conclusion
Addition of buprenorphine (60 μg) or dexmedetomidine (5 μg) to intrathecal bupivacaine for transurethral resection prolongs the time to the first analgesic request with comparable recovery profile.
Background: The supplementation of local anaesthetics with
adjuvants to improve the efficacy of subarachnoid block has
been recognised since long. The most preferred drug has been
opioids, but newer drugs like dexmedetomidine has also been
introduced and investigated as an effective adjuvant.
Aim: This study was conducted to evaluate and compare
the characteristics of subarachnoid blockade, hemodynamic
stability and adverse effects of intrathecal buprenorphine and
intrathecal dexmedetomidine as an adjuvant to 0.5% hyperbaric
bupivacaine for lower abdominal surgeries.
Materials and Methods: The present study included 60 patients
aged between 18-60 years classified as American Society of
Anesthesiologists (ASA) Physical Status (PS) I/II scheduled for
elective lower abdominal surgeries. The patients were randomly
allotted to two groups to receive intrathecal 3ml of 0.5%
bupivacine with 60µg of buprenorphine (Group B; n=30) or
3ml of 0.5% bupivacaine with 5µg of dexmedetomidine (Group
D; n=30). The onset time to peak sensory level, motor block,
sedation, Haemodynamic variables, duration of motor block,
analgesia and any adverse effects were noted.
Results: There was no significant difference between groups
regarding demographic characteristics and type of surgery. The
motor, sensory blockade and time of rescue analgesia were
significantly prolonged in Group D compared to Group B. The
sedation level was higher in Group D compared to Group B.
There was no significant difference in haemodynamic variables
although Group B had lower Heart Rate (HR) than Group D.
Conclusion: Intrathecal dexmedetomidine when compared
to intrathecal buprenorphine causes prolonged anaesthesia
and analgesia with reduced need for sedation and rescue
analgesics.
Only limited information exists on the pharmacokinetics of prolonged (> 24 hours) and high-dose dexmedetomidine infusions in critically ill patients. The aim of this study was to characterize the pharmacokinetics of long dexmedetomidine infusions and to assess the dose linearity of high doses. Additionally, we wanted to quantify for the first time in humans the concentrations of H-3, a practically inactive metabolite of dexmedetomidine.
Thirteen intensive care patients with mean age of 57 years and Simplified Acute Physiology Score (SAPS) II score of 45 were included in the study. Dexmedetomidine infusion was commenced by using a constant infusion rate for the first 12 hours. After the first 12 hours, the infusion rate of dexmedetomidine was titrated between 0.1 and 2.5 μg/kg/h by using predefined dose levels to maintain sedation in the range of 0 to -3 on the Richmond Agitation-Sedation Scale. Dexmedetomidine was continued as long as required to a maximum of 14 days. Plasma dexmedetomidine and H-3 metabolite concentrations were measured, and pharmacokinetic variables were calculated with standard noncompartmental methods. Safety and tolerability were assessed by adverse events, cardiovascular signs, and laboratory tests.
The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours (117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution during the elimination phase, 223 L (35%). Altogether, 116 steady-state concentrations were found in 12 subjects. The geometric mean value for clearance at steady state was 53.1 L/h (55%). A statistically significant linear relation (r2 = 0.95; P < 0.001) was found between the areas under the dexmedetomidine plasma concentration-time curves and cumulative doses of dexmedetomidine. The elimination half-life of H-3 was 9.1 hours (37%). The ratio of AUC0-∞ of H-3 metabolite to that of dexmedetomidine was 1.47 (105%), ranging from 0.29 to 4.4. The ratio was not statistically significantly related to the total dose of dexmedetomidine or the duration of the infusion.
The results suggest linear pharmacokinetics of dexmedetomidine up to the dose of 2.5 μg/kg/h. Despite the high dose and prolonged infusions, safety findings were as expected for dexmedetomidine and the patient population.
ClinicalTrials.gov: NCT00747721.
Various adjuvants have been used with local anesthetics in spinal anesthesia to avoid intraoperative visceral and somatic pain and to provide prolonged postoperative analgesia. Dexmedetomidine, the new highly selective α2-agonist drug, is now being used as a neuraxial adjuvant. The aim of this study was to evaluate the onset and duration of sensory and motor block, hemodynamic effect, postoperative analgesia, and adverse effects of dexmedetomidine or fentanyl given intrathecally with hyperbaric 0.5% bupivacaine.
Sixty patients classified in American Society of Anesthesiologists classes I and II scheduled for lower abdominal surgeries were studied. Patients were randomly allocated to receive either 12.5 mg hyperbaric bupivacaine plus 5 μg dexmedetomidine (group D, n = 30) or 12.5 mg hyperbaric bupivacaine plus 25 μg fentanyl (group F, n = 30) intrathecal.
Patients in dexmedetomidine group (D) had a significantly longer sensory and motor block time than patients in fentanyl group (F). The mean time of sensory regression to S1 was 476±23 min in group D and 187±12 min in group F (P<0.001). The regression time of motor block to reach modified Bromage 0 was 421±21 min in group D and 149±18 min in group F (P<0.001).
Intrathecal dexmedetomidine is associated with prolonged motor and sensory block, hemodynamic stability, and reduced demand for rescue analgesics in 24 h as compared to fentanyl.
To determine the effect of adding dexmedetomidine to bupivacaine for neuraxial anesthesia.
Sixty-six patients were studied between April and May 2008 in the University of Jordan, Amman Jordan. They were randomly assigned into 3 groups, each receiving spinal bupivacaine 12.5mg combined with normal saline (group N) Dexmedetomidine 5 microg (group D5), or dexmedetomidine 10 microg (group D10). The onset times to reach T10 sensory and Bromage 3 motor block, and the regression times to reach S1 sensory level and Bromage 0 motor scale, were recorded.
The mean time of sensory block to reach the T10 dermatome was 4.7 +/- 2.0 minutes in D10 group, 6.3 +/- 2.7 minutes in D5, and 9.5 +/- 3.0 minutes in group N. The mean time to reach Bromage 3 scale was 10.4 +/- 3.4 minutes in group D10, 13.0+/-3.4 minutes in D5, and 18.0 +/- 3.3 minutes in group N. The regression time to reach S1 dermatome was 338.9 +/- 44.8 minutes in group D10, 277.1 +/- 23.2 minutes in D5, and 165.5 +/- 32.9 minutes in group N. The regression to Bromage 0 was 302.9 +/- 36.7 minutes in D10, 246.4 +/- 25.7 minutes in D5, and 140.1 +/- 32.3 minutes in group N. Onset and regression of sensory and motor block were highly significant (N vesus D5, N versus D10, and D5 versus D10, p<0.001).
Dexmedetomidine has a dose dependant effect on the onset and regression of sensory and motor block when used as an adjuvant to bupivacaine in spinal anesthesia.
Ninety patients aged 56-85 years scheduled for suprapubic prostatectomy, randomly received intrathecally either bupivacaine 30 mg (group A, n = 30), bupivacaine 30 mg plus buprenorphine 0.03 mg (group B, n = 30) or bupivacaine 30 mg plus buprenorphine 0.045 mg (group C, n = 30). Prolonged postoperative analgesia, minimal disturbance of consciousness and comfortable breathing were common to the groups that received buprenorphine. The higher concentration of buprenorphine improved the quality and duration of analgesia. The only side effects found in the buprenorphine groups were nausea and vomiting in 11 and 14 patients, respectively, in groups B and C. Our study shows that buprenorphine is an effective analgesic, suitable for the management of postoperative pain in elderly patients.
The purpose of this study was to compare the onset and duration of sensory and motor block, as well as the hemodynamic changes and level of sedation, following intrathecal bupivacaine supplemented with either dexmedetomidine or clonidine.
In a prospective, double-blind study, 60 patients undergoing transurethral resection of prostate or bladder tumor under spinal anesthesia were randomly allocated to one of three groups. Group B received 12 mg of hyperbaric bupivacaine, group D received 12 mg of bupivacaine supplemented with 3 microg of dexmedetomidine and group C received 12 mg of bupivacaine supplemented with 30 microg of clonidine. The onset times to reach peak sensory and motor levels, and the sensory and motor regression times, were recorded. Hemodynamic changes and the level of sedation were also recorded.
Patients in groups D and C had a significantly shorter onset time of motor block and significantly longer sensory and motor regression times than patients in group B. The mean time of sensory regression to the S1 segment was 303 +/- 75 min in group D, 272 +/- 38 min in group C and 190 +/- 48 min in group B (B vs. D and B vs. C, P < 0.001). The regression of motor block to Bromage 0 was 250 +/- 76 min in group D, 216 +/- 35 min in group C and 163 +/- 47 min in group B (B vs. D and B vs. C, P < 0.001). The onset and regression times were not significantly different between groups D and C. The mean arterial pressure, heart rate and level of sedation were similar in the three groups intra-operatively and post-operatively.
Dexmedetomidine (3 microg) or clonidine (30 microg), when added to intrathecal bupivacaine, produces a similar prolongation in the duration of the motor and sensory block with preserved hemodynamic stability and lack of sedation.
Comparative Study of Intrathecal Dexmedetomidine and Buprenorphine as Adjuvant to Bupivacaine in Spinal Anaesthesia in a teaching hospital
- A Parimala
A.Parimala. Comparative Study of Intrathecal Dexmedetomidine and Buprenorphine as
Adjuvant to Bupivacaine in Spinal Anaesthesia in a teaching hospital. International
Journal of Health and Clinical Research, 2021;4 (10):7-11.
Intrathecal Buprenorphine or intrathecal Dexmedetomidine for postoperative analgesia: A comparative study.The Health Agenda
- P Soumya Samal
- Chandrasekar Rani
- Saubhagya Lj
- Jena Kumar
Soumya Samal, P. Rani, Chandrasekar LJ and Saubhagya Kumar Jena. Intrathecal
Buprenorphine or intrathecal Dexmedetomidine for postoperative analgesia: A
comparative study.The Health Agenda, Volume 2. Issue 1. January, 2014.
Dexmedetomidine and Buprenorphine as Adjuvant to Bupivacaine in Spinal Anaesthesia -A comparative study
- B Maharani
- Prakash
- N Paramesh Kalaiah
- Elango
B Maharani, M sathya Prakash, Paramesh kalaiah, N.C Elango. Dexmedetomidine and
Buprenorphine as Adjuvant to Bupivacaine in Spinal Anaesthesia -A comparative study.
Int J Cur Res Rev, June 2013/ Vol 05 (11).
Comparative Study of Intrathecal Dexmedetomidine and Buprenorphine as Adjuvant to Bupivacaine in Spinal Anesthesia: A Randomized Controlled Trail
- K Bojaraaj
- S Vijayaragavan
- S Senthilkumar
- Mam Khan
Bojaraaj K, Vijayaragavan S, Senthilkumar S, Khan MAM. Comparative Study of
Intrathecal Dexmedetomidine and Buprenorphine as Adjuvant to Bupivacaine in Spinal
Anesthesia: A Randomized Controlled Trail. Int J Sci Stud 2016;4(1):248-253.
studied dose related effect of intrathecal Dexmedetomidine with hyperbaric bupivacaine-a prospective randomized double blind study
- E A Hala
- Eid
Hala E A Eid et al 2011 studied dose related effect of intrathecal Dexmedetomidine with
hyperbaric bupivacaine-a prospective randomized double blind study. Ain Shams
Journal of Anesthesiology.2011 July;4(2);83-95.
Effect of Dexmedetomidine added to spinal Bupivacaine for urological procedure
- Al Mustafa
- M M Abu- Halaweh
- S A Aloweidi
- A S Murshidi
- M M Ammari
- B A Awward
Comparative study of intrathecal clonidine and intrathecal Buprenorphine for postoperative analgesia after lower limb orthopaedic surgery
- P S Sapkal
- K D Kulkarni
- S S Rajurkar
- Nandedkar Pd
Sapkal PS, Kulkarni KD, Rajurkar SS, Nandedkar pd. Comparative study of intrathecal
clonidine and intrathecal Buprenorphine for postoperative analgesia after lower limb
orthopaedic surgery.International journal current Res Rev. 2013;5:87-91.
A comparative study of intrathecal Dexmedetomidine and Fentanyl as adjuvants to Bupivacaine
- R Gupta
- R Varma
- J Bogra
- M Kohli
- R Raman
- J K Kushwala
Gupta R, Varma R, Bogra J, Kohli M, Raman R, Kushwala J K. A comparative study of
intrathecal Dexmedetomidine and Fentanyl as adjuvants to Bupivacaine. Journal of
Anaesthesiology and clinical Pharmacology|July-september 2011 | vol 27 | issue 3.